MedTrace Logo

Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction

NCT04469998 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2023-07-21

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety, tolerability and efficacy of AXR-270 Cream in treating posterior blepharitis associated with Meibomian Gland Disease (MGD)

Conditions

  • Posterior Blepharitis
  • Meibomian Gland Dysfunction

Interventions

DRUG

AXR-270 Low Dose

AXR-270 Topical Eyelid Cream

DRUG

AXR-270 High Dose

AXR-270 Topical Eyelid Cream

DRUG

AXR-270 Vehicle

AXR-270 Topical Eyelid Cream Vehicle

Sponsors & Collaborators

  • AxeroVision, Inc.

    lead INDUSTRY

Principal Investigators

  • Houman D Hemmati, MD, PhD · AxeroVision, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-16
Primary Completion
2020-12-01
Completion
2020-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04469998 on ClinicalTrials.gov